RNA Editing for Neurodegenerative Diseases Market
RNA Editing for Neurodegenerative Diseases Market Analysis - Size, Share, and Forecast Outlook 2025 to 2035
The Global RNA Editing For Neurodegenerative Diseases Market Is Projected To Grow From USD 125.0 Million In 2025 To USD 847.9 Million By 2035, Advancing At A CAGR Of 21.1%. ADAR-Based Editing Is Expected To Lead The Market With A 60.0% Share In 2025, While Biopharmaceutical Companies Are Anticipated To Account For 70.0% Of The End-User Segment.
FREE CustomizationRNA Editing for Neurodegenerative Diseases Market Forecast and Outlook 2025 to 2035
The global RNA editing for neurodegenerative diseases market is projected to grow from USD 125.0 million in 2025 to approximately USD 847.9 million by 2035, recording an absolute increase of USD 725.0 million over the forecast period.
This translates into a total growth of 580.0%, with the market forecast to expand at a compound annual growth rate (CAGR) of 21.1% between 2025 and 2035. The overall market size is expected to grow by nearly 6.8X during the same period, supported by increasing prevalence of neurodegenerative diseases, rising investment in gene therapy research, and growing emphasis on precision medicine approaches for complex neurological disorders.
Quick Stats for RNA Editing for Neurodegenerative Diseases Market
- RNA Editing for Neurodegenerative Diseases Market Value (2025): USD 125.0 million
- RNA Editing for Neurodegenerative Diseases Market Forecast Value (2035): USD 847.9 million
- RNA Editing for Neurodegenerative Diseases Market Forecast CAGR: 21.1%
- Leading Technology in RNA Editing for Neurodegenerative Diseases Market: ADAR-based Editing (60.0%)
- Key Growth Regions in RNA Editing for Neurodegenerative Diseases Market: North America, Europe, and Asia Pacific
- Key Players in RNA Editing for Neurodegenerative Diseases Market: Shape Therapeutics, Korro Bio, ProQR Therapeutics, Wave Life Sciences, Roche, Biogen, Novartis, Bristol Myers Squibb, Alnylam Pharmaceuticals, Ionis Pharmaceuticals
Between 2025 and 2030, the RNA editing for neurodegenerative diseases market is projected to expand from USD 125.0 million to USD 318.5 million, resulting in a value increase of USD 193.5 million, which represents 26.7% of the total forecast growth for the decade. This phase of growth will be shaped by advancing clinical trial programs, increasing regulatory approvals for gene therapy applications, and growing investment in RNA editing technology platforms. Biotechnology companies are expanding their RNA editing portfolios to address the growing demand for innovative treatment solutions for Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.
RNA Editing for Neurodegenerative Diseases Market Key Takeaways
| Metric | Value |
|---|---|
| Estimated Value in (2025E) | USD 125.0 million |
| Forecast Value in (2035F) | USD 847.9 million |
| Forecast CAGR (2025 to 2035) | 21.1% |
From 2030 to 2035, the market is forecast to grow from USD 318.5 million to USD 847.9 million, adding another USD 531.5 million, which constitutes 73.3% of the overall ten-year expansion. This period is expected to be characterized by commercialization of advanced RNA editing therapies, integration of artificial intelligence in drug development, and expansion of personalized medicine applications for neurological disorders. The growing adoption of precision medicine approaches and increasing pharmaceutical industry investment in neurodegenerative disease research will drive demand for sophisticated RNA editing technologies with enhanced safety profiles and therapeutic efficacy.
Between 2020 and 2025, the RNA editing for neurodegenerative diseases market experienced exponential expansion, driven by breakthrough research developments and growing recognition of RNA editing potential in treating previously untreatable neurological conditions. The market developed as biopharmaceutical companies recognized the transformative opportunity for addressing genetic causes of neurodegenerative diseases through precise RNA modification approaches. Research initiatives and clinical trial advancement began emphasizing the importance of RNA editing technologies in achieving breakthrough therapeutic outcomes for complex neurological disorders.
Why is the RNA Editing for Neurodegenerative Diseases Market Growing?
Market expansion is being supported by the increasing prevalence of neurodegenerative diseases and corresponding need for innovative therapeutic approaches that can address the genetic and molecular causes of these complex disorders. Modern biopharmaceutical research is increasingly focused on RNA editing technologies that can provide precise molecular intervention, correct disease-causing mutations, and restore normal cellular function in neurological tissues. The revolutionary potential of RNA editing in treating previously incurable neurodegenerative conditions makes it an essential component of next-generation therapeutic development.
The growing emphasis on precision medicine and personalized therapy approaches is driving demand for advanced RNA editing solutions that address specific genetic variants and molecular pathways associated with neurodegenerative diseases. Pharmaceutical company preferences for therapeutic platforms that combine precision targeting, reduced off-target effects, and comprehensive molecular intervention capabilities are creating opportunities for innovative RNA editing technology development. The rising influence of aging population demographics and increasing healthcare burden of neurodegenerative diseases is also contributing to increased investment in RNA editing research and development across different therapeutic applications.
Segmental Analysis
The market is segmented by disease type, technology, end user, and region. By disease type, the market is divided into Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, and others. Based on technology, the market is categorized into ADAR-based editing, guide RNA systems, and other technologies. In terms of end user, the market is segmented into biopharmaceutical companies, research institutes, and contract research organizations. Regionally, the market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
By Technology, ADAR-based Editing Segment Accounts for 60.0% Market Share
The ADAR-based editing segment is projected to account for 60.0% of the RNA editing for neurodegenerative diseases market in 2025, reaffirming its position as the category's dominant technology platform. Biopharmaceutical researchers increasingly recognize the therapeutic advantages of ADAR-based editing systems, particularly their ability to provide precise adenosine-to-inosine editing, endogenous enzyme utilization, and reduced immunogenicity compared to other RNA editing approaches. This technology platform addresses both precision editing requirements and safety considerations, providing essential capabilities for neurodegenerative disease therapeutic development.
This technology type forms the foundation of most advanced RNA editing therapeutic programs, as it represents the most clinically validated and operationally reliable approach to RNA modification in neurological applications. Clinical trial results and preclinical validation continue to strengthen confidence in ADAR-based systems. With increasing recognition of the safety requirements in neurological therapeutic development and the importance of precise molecular intervention, ADAR-based editing aligns with both immediate therapeutic needs and long-term commercialization objectives, making it the central growth driver of RNA editing technology demand.
By Disease Type, Alzheimer's Disease Segment Accounts for 35.0% Market Share
Alzheimer's disease applications are projected to represent 35.0% of RNA editing for neurodegenerative diseases demand in 2025, underscoring their role as the primary therapeutic focus driving research investment and technology development. Biopharmaceutical researchers recognize that Alzheimer's disease represents the largest patient population, highest unmet medical need, and greatest commercial opportunity within neurodegenerative disease therapeutic development. Alzheimer's applications offer enhanced market potential through large patient populations and significant healthcare burden reduction opportunities.
The segment is supported by the widespread nature of Alzheimer's disease affecting millions of patients globally and the growing recognition that RNA editing technologies can address specific genetic variants and molecular pathways associated with disease progression. Additionally, pharmaceutical companies are increasingly investing in Alzheimer's research programs that can leverage RNA editing for disease modification rather than symptomatic treatment. As neurodegenerative disease research advances toward precision medicine approaches, Alzheimer's disease applications will continue to play a crucial role in comprehensive therapeutic development strategies, reinforcing their essential position within the RNA editing market.
By End User, Biopharmaceutical Companies Segment Accounts for 70.0% Market Share
The biopharmaceutical companies segment is forecasted to contribute 70.0% of the RNA editing for neurodegenerative diseases market in 2025, reflecting their central role in therapeutic development, clinical research, and commercialization activities.
Biopharmaceutical companies possess the financial resources, regulatory expertise, and clinical development capabilities required for advancing RNA editing therapeutics from research through commercial approval, making them the cornerstone of market development. This end-user segment provides essential market drivers including research funding, clinical trial execution, and regulatory pathway navigation.
The segment benefits from established relationships between biopharmaceutical companies and RNA editing technology providers, who offer comprehensive platform licensing and ongoing technical support services. Biopharmaceutical companies also provide advantages in terms of clinical development expertise, regulatory knowledge, and commercial infrastructure for therapeutic launch. With growing emphasis on precision medicine and breakthrough therapy development, biopharmaceutical companies serve as critical enablers for RNA editing therapeutic advancement, making them fundamental drivers of market growth and technology commercialization.
What are the Drivers, Restraints, and Key Trends of the RNA Editing for Neurodegenerative Diseases Market?
The RNA editing for neurodegenerative diseases market is advancing rapidly due to increasing prevalence of neurological disorders and growing investment in gene therapy research. However, the market faces challenges including complex regulatory pathways, safety validation requirements, and concerns about delivery system optimization for central nervous system applications. Innovation in delivery technologies and artificial intelligence-guided editing systems continue to influence research development and market expansion patterns.
Expansion of Artificial Intelligence and Machine Learning in Drug Development
The growing adoption of AI and ML technologies is enabling more sophisticated RNA editing target identification and therapeutic optimization capabilities. AI-enhanced drug development platforms offer comprehensive target validation, including molecular pathway analysis, off-target prediction, and clinical outcome modeling that are particularly important for complex neurodegenerative disease applications. Machine learning integration provides access to precision medicine approaches and improved therapeutic design through computational biology insights.
Integration of Advanced Delivery Technologies and CNS-Targeted Systems
Modern RNA editing companies are incorporating advanced delivery technologies such as lipid nanoparticles, viral vectors, and blood-brain barrier crossing systems to enhance central nervous system targeting and therapeutic efficacy. These technologies improve drug delivery efficiency, enable targeted neuronal cell uptake, and provide better therapeutic outcomes for neurodegenerative disease applications. Advanced delivery systems also enable reduced systemic exposure and improved safety profiles throughout the therapeutic treatment process.
Analysis of RNA Editing for Neurodegenerative Diseases Market by Key Country
| Country | CAGR (2025-2035) |
|---|---|
| United States | 23.5% |
| Germany | 22.8% |
| UK | 22.1% |
| Japan | 21.4% |
| France | 20.7% |
| South Korea | 20.0% |
The RNA editing for neurodegenerative diseases market is experiencing exceptional growth globally, with the United States leading at a 23.5% CAGR through 2035, driven by comprehensive biotechnology ecosystem, extensive research funding, and advanced clinical trial infrastructure. Germany follows at 22.8%, supported by pharmaceutical industry excellence, comprehensive research institutions, and strong government support for biotechnology innovation.
The UK shows growth at 22.1%, emphasizing biomedical research leadership and comprehensive drug development capabilities. Japan records 21.4% growth, focusing on advanced biomedical research and aging population healthcare needs. France demonstrates 20.7% growth, representing established pharmaceutical industry and comprehensive neurological research programs.
The report covers an in-depth analysis of 40+ countries; six top-performing countries are highlighted below.
United States Demonstrates Market Leadership with Biotechnology Excellence
Demand for RNA editing technologies in the USA is projected to grow at a CAGR of 23.5%, supported by comprehensive biotechnology ecosystem and established biopharmaceutical research infrastructure. American biotechnology companies consistently invest in cutting-edge gene therapy research for competitive advantage and therapeutic breakthrough. The market is characterized by mature research capabilities, comprehensive funding ecosystems, and established relationships between biotechnology companies and academic research institutions.
- Biotechnology innovation leadership and pharmaceutical research excellence are supporting continued investment in advanced RNA editing technologies throughout biopharmaceutical and research applications.
- Research funding networks and regulatory expertise are facilitating access to cutting-edge therapeutic development while ensuring appropriate clinical validation and safety assessment.
Germany Demonstrates Strong Growth with Pharmaceutical Industry Leadership
Revenue from RNA editing research in Germany is projected to grow at a CAGR of 22.8% through 2035, driven by pharmaceutical industry excellence, comprehensive biotechnology research capabilities, and systematic approach to drug development advancement. German biopharmaceutical companies consistently utilize advanced research technologies as part of integrated drug discovery systems, emphasizing scientific rigor and therapeutic innovation.
- Pharmaceutical industry leadership and biotechnology research programs are maintaining strong demand for RNA editing technologies across diverse therapeutic development and research applications.
- Research institution development programs and drug discovery advancement initiatives are supporting continued innovation and appropriate utilization of advanced genetic medicine technologies.
United Kingdom Shows Promising Growth with Biomedical Research Excellence
Revenue from RNA editing research in the UK is projected to grow at a CAGR of 22.1% through 2035, driven by biomedical research excellence, comprehensive pharmaceutical development capabilities, and growing emphasis on precision medicine applications. British research institutions are increasingly adopting RNA editing technologies for therapeutic advancement and scientific discovery, supported by expanding biotechnology capabilities and improved integration with pharmaceutical industry partnerships.
- Biomedical research excellence and pharmaceutical industry collaboration are supporting increased availability of RNA editing technologies across diverse research and therapeutic development applications.
- Growing collaboration between international biotechnology companies and domestic research institutions is enhancing technology access and scientific expertise in RNA editing applications and therapeutic development.
Japan Demonstrates Stable Growth with Advanced Biomedical Research
Revenue from RNA editing research in Japan is projected to grow at a CAGR of 21.4% through 2035, supported by advanced biomedical research infrastructure, comprehensive aging population healthcare programs, and systematic approach to neurological disease research. Japanese research institutions consistently utilize advanced biotechnology approaches as part of integrated research systems, emphasizing scientific excellence and therapeutic innovation.
- Advanced biomedical research and aging population healthcare programs are maintaining stable demand for RNA editing technologies across comprehensive neurological disease research applications.
- Research development programs and biotechnology advancement initiatives are supporting continued innovation and appropriate utilization of genetic medicine technologies.
France Demonstrates Growth with Pharmaceutical Research Excellence
Revenue from RNA editing research in France is projected to grow at a CAGR of 20.7% through 2035, supported by established pharmaceutical industry, comprehensive research institutions, and systematic approach to neurological disease research that facilitates appropriate use of RNA editing technologies for diverse therapeutic applications. French research organizations consistently utilize established advanced biotechnology approaches, emphasizing scientific rigor and therapeutic development within integrated pharmaceutical research systems.
- Pharmaceutical industry excellence and neurological disease research programs are supporting systematic adoption of RNA editing technologies across research and therapeutic development applications.
- Research excellence programs and biotechnology development initiatives are maintaining high standards for RNA editing utilization and therapeutic development optimization.
South Korea Anchors Growth with Biotechnology Innovation Focus
Revenue from RNA editing research in South Korea is projected to grow at a CAGR of 20.0% through 2035, supported by biotechnology innovation programs, comprehensive research infrastructure development, and systematic approach to advanced therapeutic research. South Korean research institutions emphasize cutting-edge biotechnology utilization within structured innovation frameworks that prioritize scientific advancement and therapeutic development excellence.
- Biotechnology innovation programs and advanced research development are supporting stable adoption of RNA editing technologies across diverse therapeutic research and biotechnology applications.
- Research advancement initiatives and biotechnology industry development are maintaining growth in genetic medicine technology adoption and scientific support for optimal therapeutic development performance.
Europe Market Split by Country
The RNA editing for neurodegenerative diseases market in Europe is projected to expand rapidly through 2035, supported by increasing emphasis on biotechnology research excellence, rising investment in pharmaceutical innovation, and ongoing advancement in genetic medicine technologies. Germany will continue to lead the regional market, accounting for 28.7% in 2025 and rising to 29.5% by 2035, supported by pharmaceutical industry leadership, comprehensive biotechnology research infrastructure, and robust drug development capabilities. The United Kingdom follows with 24.3% in 2025, declining to 23.8% by 2035, driven by established biomedical research institutions, advanced pharmaceutical companies, and comprehensive neurological disease research programs.
France holds 16.9% in 2025, increasing to 18.2% by 2035 as research institutions expand RNA editing research adoption and demand grows for advanced genetic medicine technologies. Italy contributes 9.8% in 2025, adjusting to 9.1% by 2035, supported by pharmaceutical research development and biotechnology advancement programs. Spain represents 7.2% in 2025, moving to 7.8% by 2035, underpinned by expanding research infrastructure and growing emphasis on neurological disease research.
Nordic Countries account for 8.5% in 2025, increasing to 9.2% by 2035, supported by advanced research systems and comprehensive biotechnology innovation programs. BENELUX markets together represent 3.8% in 2025, declining to 2.1% by 2035, with demand influenced by regional research development and biotechnology advancement patterns. The Rest of Western Europe moderates from 0.8% in 2025 to 0.3% by 2035, as larger core markets capture greater share of RNA editing technology investment and pharmaceutical research development.
Japan Segmental Share by Country
The RNA editing for neurodegenerative diseases market in Japan is set to remain concentrated in Alzheimer's research applications in 2025, reflecting disease prevalence patterns and research priority focus. Alzheimer's Research dominates with a 42.6% share in 2025, supported by Japan's aging population demographics, comprehensive neurological disease research programs, and growing emphasis on precision medicine approaches for cognitive disorders.
Parkinson's Research represents 28.9% in 2025, maintaining significant presence due to disease prevalence, advanced neurological research capabilities, and increasing emphasis on movement disorder therapeutic development. ALS Research holds 18.7%, sustained by comprehensive neuromuscular disease research programs, clinical trial infrastructure, and increasing investment in rare neurological disease research.
The remaining 9.8% is attributed to other research applications, reflecting the growing role of specialized neurological disease research and emerging RNA editing applications entering Japanese biomedical research and therapeutic development segments.
South Korea Segmental Share by Country
The RNA editing for neurodegenerative diseases market in South Korea in 2025 is shaped by strong emphasis on pharmaceutical industry development and comprehensive biotechnology innovation, reflecting both industrial priorities and research advancement objectives. Pharmaceutical Companies account for the largest share at 52.4%, supported by South Korea's pharmaceutical industry development, biotechnology innovation programs, and increasing emphasis on advanced therapeutic research and development.
Biotechnology Firms follow with 28.3%, driven by biotechnology sector growth, comprehensive research capabilities, and growing emphasis on genetic medicine and precision therapy development. Academic Institutions contributes 12.8%, supported by research excellence programs, neurological disease research capabilities, and increasing investment in advanced biotechnology research applications.
The remaining 6.5% is attributed to government research and other applications, including specialized research institutions, clinical development organizations, and emerging RNA editing research categories, highlighting opportunities for expanded biotechnology applications and comprehensive therapeutic development advancement.
Competitive Landscape of RNA Editing for Neurodegenerative Diseases Market
The RNA editing for neurodegenerative diseases market is characterized by competition among innovative biotechnology companies, established pharmaceutical corporations, and specialized genetic medicine developers. Companies are investing in advanced platform technologies, clinical development programs, regulatory expertise, and strategic partnerships to deliver breakthrough therapeutic solutions for complex neurological disorders. Technology development, clinical validation, and regulatory pathway execution are central to strengthening therapeutic portfolios and market positioning in precision medicine applications.
Shape Therapeutics leads the market with 22.8% global value share, offering comprehensive RNA editing platforms with a focus on ADAR-based therapeutic development and neurological disease applications. Korro Bio provides specialized RNA editing technologies with emphasis on precision medicine and central nervous system targeting. ProQR Therapeutics focuses on innovative RNA therapeutics and comprehensive genetic medicine development. Wave Life Sciences delivers advanced oligonucleotide technologies with strong emphasis on neurological disorder applications.
Roche operates with focus on comprehensive pharmaceutical development and neurological disease research programs. Biogen provides specialized neurological therapeutics with emphasis on breakthrough therapy development and precision medicine approaches. Novartis specializes in advanced pharmaceutical research and comprehensive neurological disease therapeutic portfolios. Bristol Myers Squibb, Alnylam Pharmaceuticals, and Ionis Pharmaceuticals provide comprehensive biotechnology solutions to enhance market therapeutic diversity and serve various neurological disease research applications across different therapeutic development requirements and precision medicine advancement scenarios.
Key Players in the RNA Editing for Neurodegenerative Diseases Market
- Shape Therapeutics
- Korro Bio
- ProQR Therapeutics
- Wave Life Sciences
- Roche
- Biogen
- Novartis
- Bristol Myers Squibb
- Alnylam Pharmaceuticals
- Ionis Pharmaceuticals
Scope of the Report
| Items | Values |
|---|---|
| Quantitative Units (2025) | USD 125.0 Million |
| Disease Type | Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease, Others |
| Technology | ADAR-based Editing, Guide RNA Systems, Other Technologies |
| End User | Biopharmaceutical Companies, Research Institutes, Contract Research Organizations |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Countries Covered | United States, Germany, United Kingdom, Japan, France, South Korea, Italy, Spain, Nordic Countries and 40+ countries |
| Key Companies Profiled | Shape Therapeutics, Korro Bio, ProQR Therapeutics, Wave Life Sciences, Roche, Biogen, Novartis, Bristol Myers Squibb, Alnylam Pharmaceuticals, Ionis Pharmaceuticals |
| Additional Attributes | Dollar sales by disease type and technology category, regional research trends, competitive landscape, pharmaceutical company preferences for specific RNA editing platforms, integration with drug development programs, innovations in delivery technologies, therapeutic efficacy optimization, and precision medicine advancement |
RNA Editing for Neurodegenerative Diseases Market by Segments
-
Disease Type :
- Alzheimer's Disease
- Parkinson's Disease
- ALS
- Huntington's Disease
- Others
-
Technology :
- ADAR-based Editing
- Guide RNA Systems
- Other Technologies
-
End User :
- Biopharmaceutical Companies
- Research Institutes
- Contract Research Organizations
-
Region :
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic Countries
- BENELUX
- Rest of Western Europe
- Asia Pacific
- Japan
- South Korea
- China
- India
- Australia
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
- North America
Table of Content
- Executive Summary
- Global Market Outlook
- Demand-side Trends
- Supply-side Trends
- Technology Roadmap Analysis
- Analysis and Recommendations
- Market Overview
- Market Coverage / Taxonomy
- Market Definition / Scope / Limitations
- Market Background
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Trends
- Scenario Forecast
- Demand in Optimistic Scenario
- Demand in Likely Scenario
- Demand in Conservative Scenario
- Opportunity Map Analysis
- Product Life Cycle Analysis
- Supply Chain Analysis
- Investment Feasibility Matrix
- Value Chain Analysis
- PESTLE and Porter’s Analysis
- Regulatory Landscape
- Regional Parent Market Outlook
- Production and Consumption Statistics
- Import and Export Statistics
- Market Dynamics
- Global Market Analysis 2020-2024 and Forecast, 2025-2035
- Historical Market Size Value (USD Million) & Units Analysis, 2020-2024
- Current and Future Market Size Value (USD Million) & Units Projections, 2025-2035
- Y-o-Y Growth Trend Analysis
- Absolute $ Opportunity Analysis
- Global Market Pricing Analysis 2020-2024 and Forecast 2025-2035
- Global Market Analysis 2020-2024 and Forecast 2025-2035, By Disease Type
- Introduction / Key Findings
- Historical Market Size Value (USD Million) & Units Analysis By Disease Type, 2020-2024
- Current and Future Market Size Value (USD Million) & Units Analysis and Forecast By Disease Type, 2025-2035
- Alzheimer's Disease
- Parkinson's Disease
- ALS
- Huntington's Disease
- Others
- Y-o-Y Growth Trend Analysis By Disease Type, 2020-2024
- Absolute $ Opportunity Analysis By Disease Type, 2025-2035
- Global Market Analysis 2020-2024 and Forecast 2025-2035, By Technology
- Introduction / Key Findings
- Historical Market Size Value (USD Million) & Units Analysis By Technology, 2020-2024
- Current and Future Market Size Value (USD Million) & Units Analysis and Forecast By Technology, 2025-2035
- ADAR-based Editing
- Guide RNA Systems
- Other Technologies
- Y-o-Y Growth Trend Analysis By Technology, 2020-2024
- Absolute $ Opportunity Analysis By Technology, 2025-2035
- Global Market Analysis 2020-2024 and Forecast 2025-2035, By End User
- Introduction / Key Findings
- Historical Market Size Value (USD Million) & Units Analysis By End User, 2020-2024
- Current and Future Market Size Value (USD Million) & Units Analysis and Forecast By End User, 2025-2035
- Biopharmaceutical Companies
- Research Institutes
- Contract Research Organizations
- Y-o-Y Growth Trend Analysis By End User, 2020-2024
- Absolute $ Opportunity Analysis By End User, 2025-2035
- Global Market Analysis 2020-2024 and Forecast 2025-2035, By Region
- Introduction
- Historical Market Size Value (USD Million) & Units Analysis By Region, 2020-2024
- Current Market Size Value (USD Million) & Units Analysis and Forecast By Region, 2025-2035
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia & Pacific
- Middle East & Africa
- Market Attractiveness Analysis By Region
- North America Market Analysis 2020-2024 and Forecast 2025-2035, By Country
- Historical Market Size Value (USD Million) & Units Trend Analysis By Market Taxonomy, 2020-2024
- Market Size Value (USD Million) & Units Forecast By Market Taxonomy, 2025-2035
- By Country
- U.S.
- Canada
- Mexico
- By Disease Type
- By Technology
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Disease Type
- By Technology
- By End User
- Key Takeaways
- Latin America Market Analysis 2020-2024 and Forecast 2025-2035, By Country
- Historical Market Size Value (USD Million) & Units Trend Analysis By Market Taxonomy, 2020-2024
- Market Size Value (USD Million) & Units Forecast By Market Taxonomy, 2025-2035
- By Country
- Brazil
- Chile
- Rest of Latin America
- By Disease Type
- By Technology
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Disease Type
- By Technology
- By End User
- Key Takeaways
- Western Europe Market Analysis 2020-2024 and Forecast 2025-2035, By Country
- Historical Market Size Value (USD Million) & Units Trend Analysis By Market Taxonomy, 2020-2024
- Market Size Value (USD Million) & Units Forecast By Market Taxonomy, 2025-2035
- By Country
- Germany
- U.K.
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Europe
- By Disease Type
- By Technology
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Disease Type
- By Technology
- By End User
- Key Takeaways
- Eastern Europe Market Analysis 2020-2024 and Forecast 2025-2035, By Country
- Historical Market Size Value (USD Million) & Units Trend Analysis By Market Taxonomy, 2020-2024
- Market Size Value (USD Million) & Units Forecast By Market Taxonomy, 2025-2035
- By Country
- Russia
- Poland
- Hungary
- Balkan & Baltics
- Rest of Eastern Europe
- By Disease Type
- By Technology
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Disease Type
- By Technology
- By End User
- Key Takeaways
- East Asia Market Analysis 2020-2024 and Forecast 2025-2035, By Country
- Historical Market Size Value (USD Million) & Units Trend Analysis By Market Taxonomy, 2020-2024
- Market Size Value (USD Million) & Units Forecast By Market Taxonomy, 2025-2035
- By Country
- China
- Japan
- South Korea
- By Disease Type
- By Technology
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Disease Type
- By Technology
- By End User
- Key Takeaways
- South Asia & Pacific Market Analysis 2020-2024 and Forecast 2025-2035, By Country
- Historical Market Size Value (USD Million) & Units Trend Analysis By Market Taxonomy, 2020-2024
- Market Size Value (USD Million) & Units Forecast By Market Taxonomy, 2025-2035
- By Country
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia & Pacific
- By Disease Type
- By Technology
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Disease Type
- By Technology
- By End User
- Key Takeaways
- Middle East & Africa Market Analysis 2020-2024 and Forecast 2025-2035, By Country
- Historical Market Size Value (USD Million) & Units Trend Analysis By Market Taxonomy, 2020-2024
- Market Size Value (USD Million) & Units Forecast By Market Taxonomy, 2025-2035
- By Country
- Kingdom of Saudi Arabia
- Other GCC Countries
- Turkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
- By Disease Type
- By Technology
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Disease Type
- By Technology
- By End User
- Key Takeaways
- Key Countries Market Analysis
- U.S.
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- Canada
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- Mexico
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- Brazil
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- Chile
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- Germany
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- U.K.
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- Italy
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- Spain
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- France
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- Nordic
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- BENELUX
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- Russia
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- Poland
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- Hungary
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- Balkan & Baltics
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- China
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- Japan
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- South Korea
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- India
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- ASEAN
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- Australia & New Zealand
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- Kingdom of Saudi Arabia
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- Turkiye
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- South Africa
- Pricing Analysis
- Market Share Analysis, 2024
- By Disease Type
- By Technology
- By End User
- U.S.
- Market Structure Analysis
- Competition Dashboard
- Competition Benchmarking
- Market Share Analysis of Top Players
- By Regional
- By Disease Type
- By Technology
- By End User
- Competition Analysis
- Competition Deep Dive
- Shape Therapeutics
- Overview
- Product Portfolio
- Profitability by Market Segments (Product/Age /Sales Channel/Region)
- Sales Footprint
- Strategy Overview
- Korro Bio
- ProQR Therapeutics
- Wave Life Sciences
- Roche
- Biogen
- Novartis
- Bristol Myers Squibb
- Alnylam Pharmaceuticals
- Ionis Pharmaceuticals
- Shape Therapeutics
- Competition Deep Dive
- Assumptions & Acronyms Used
- Research Methodology
List Of Table
- Table 1: Global Market Value (USD Million) Forecast by Region, 2020 to 2035
- Table 2: Global Market Units Forecast by Region, 2020 to 2035
- Table 3: Global Market Value (USD Million) Forecast by Disease Type, 2020 to 2035
- Table 4: Global Market Units Forecast by Disease Type, 2020 to 2035
- Table 5: Global Market Value (USD Million) Forecast by Technology, 2020 to 2035
- Table 6: Global Market Units Forecast by Technology, 2020 to 2035
- Table 7: Global Market Value (USD Million) Forecast by End User, 2020 to 2035
- Table 8: Global Market Units Forecast by End User, 2020 to 2035
- Table 9: North America Market Value (USD Million) Forecast by Country, 2020 to 2035
- Table 10: North America Market Units Forecast by Country, 2020 to 2035
- Table 11: North America Market Value (USD Million) Forecast by Disease Type, 2020 to 2035
- Table 12: North America Market Units Forecast by Disease Type, 2020 to 2035
- Table 13: North America Market Value (USD Million) Forecast by Technology, 2020 to 2035
- Table 14: North America Market Units Forecast by Technology, 2020 to 2035
- Table 15: North America Market Value (USD Million) Forecast by End User, 2020 to 2035
- Table 16: North America Market Units Forecast by End User, 2020 to 2035
- Table 17: Latin America Market Value (USD Million) Forecast by Country, 2020 to 2035
- Table 18: Latin America Market Units Forecast by Country, 2020 to 2035
- Table 19: Latin America Market Value (USD Million) Forecast by Disease Type, 2020 to 2035
- Table 20: Latin America Market Units Forecast by Disease Type, 2020 to 2035
- Table 21: Latin America Market Value (USD Million) Forecast by Technology, 2020 to 2035
- Table 22: Latin America Market Units Forecast by Technology, 2020 to 2035
- Table 23: Latin America Market Value (USD Million) Forecast by End User, 2020 to 2035
- Table 24: Latin America Market Units Forecast by End User, 2020 to 2035
- Table 25: Western Europe Market Value (USD Million) Forecast by Country, 2020 to 2035
- Table 26: Western Europe Market Units Forecast by Country, 2020 to 2035
- Table 27: Western Europe Market Value (USD Million) Forecast by Disease Type, 2020 to 2035
- Table 28: Western Europe Market Units Forecast by Disease Type, 2020 to 2035
- Table 29: Western Europe Market Value (USD Million) Forecast by Technology, 2020 to 2035
- Table 30: Western Europe Market Units Forecast by Technology, 2020 to 2035
- Table 31: Western Europe Market Value (USD Million) Forecast by End User, 2020 to 2035
- Table 32: Western Europe Market Units Forecast by End User, 2020 to 2035
- Table 33: Eastern Europe Market Value (USD Million) Forecast by Country, 2020 to 2035
- Table 34: Eastern Europe Market Units Forecast by Country, 2020 to 2035
- Table 35: Eastern Europe Market Value (USD Million) Forecast by Disease Type, 2020 to 2035
- Table 36: Eastern Europe Market Units Forecast by Disease Type, 2020 to 2035
- Table 37: Eastern Europe Market Value (USD Million) Forecast by Technology, 2020 to 2035
- Table 38: Eastern Europe Market Units Forecast by Technology, 2020 to 2035
- Table 39: Eastern Europe Market Value (USD Million) Forecast by End User, 2020 to 2035
- Table 40: Eastern Europe Market Units Forecast by End User, 2020 to 2035
- Table 41: East Asia Market Value (USD Million) Forecast by Country, 2020 to 2035
- Table 42: East Asia Market Units Forecast by Country, 2020 to 2035
- Table 43: East Asia Market Value (USD Million) Forecast by Disease Type, 2020 to 2035
- Table 44: East Asia Market Units Forecast by Disease Type, 2020 to 2035
- Table 45: East Asia Market Value (USD Million) Forecast by Technology, 2020 to 2035
- Table 46: East Asia Market Units Forecast by Technology, 2020 to 2035
- Table 47: East Asia Market Value (USD Million) Forecast by End User, 2020 to 2035
- Table 48: East Asia Market Units Forecast by End User, 2020 to 2035
- Table 49: South Asia & Pacific Market Value (USD Million) Forecast by Country, 2020 to 2035
- Table 50: South Asia & Pacific Market Units Forecast by Country, 2020 to 2035
- Table 51: South Asia & Pacific Market Value (USD Million) Forecast by Disease Type, 2020 to 2035
- Table 52: South Asia & Pacific Market Units Forecast by Disease Type, 2020 to 2035
- Table 53: South Asia & Pacific Market Value (USD Million) Forecast by Technology, 2020 to 2035
- Table 54: South Asia & Pacific Market Units Forecast by Technology, 2020 to 2035
- Table 55: South Asia & Pacific Market Value (USD Million) Forecast by End User, 2020 to 2035
- Table 56: South Asia & Pacific Market Units Forecast by End User, 2020 to 2035
- Table 57: Middle East & Africa Market Value (USD Million) Forecast by Country, 2020 to 2035
- Table 58: Middle East & Africa Market Units Forecast by Country, 2020 to 2035
- Table 59: Middle East & Africa Market Value (USD Million) Forecast by Disease Type, 2020 to 2035
- Table 60: Middle East & Africa Market Units Forecast by Disease Type, 2020 to 2035
- Table 61: Middle East & Africa Market Value (USD Million) Forecast by Technology, 2020 to 2035
- Table 62: Middle East & Africa Market Units Forecast by Technology, 2020 to 2035
- Table 63: Middle East & Africa Market Value (USD Million) Forecast by End User, 2020 to 2035
- Table 64: Middle East & Africa Market Units Forecast by End User, 2020 to 2035
List Of Figures
- Figure 1: Global Market Units Forecast 2020 to 2035
- Figure 2: Global Market Pricing Analysis
- Figure 3: Global Market Value (USD Million) Forecast 2020 to 2035
- Figure 4: Global Market Value Share and BPS Analysis by Disease Type, 2025 and 2035
- Figure 5: Global Market Y-o-Y Growth Comparison by Disease Type, 2025 to 2035
- Figure 6: Global Market Attractiveness Analysis by Disease Type
- Figure 7: Global Market Value Share and BPS Analysis by Technology, 2025 and 2035
- Figure 8: Global Market Y-o-Y Growth Comparison by Technology, 2025 to 2035
- Figure 9: Global Market Attractiveness Analysis by Technology
- Figure 10: Global Market Value Share and BPS Analysis by End User, 2025 and 2035
- Figure 11: Global Market Y-o-Y Growth Comparison by End User, 2025 to 2035
- Figure 12: Global Market Attractiveness Analysis by End User
- Figure 13: Global Market Value (USD Million) Share and BPS Analysis by Region, 2025 and 2035
- Figure 14: Global Market Y-o-Y Growth Comparison by Region, 2025 to 2035
- Figure 15: Global Market Attractiveness Analysis by Region
- Figure 16: North America Market Incremental $ Opportunity, 2025 to 2035
- Figure 17: Latin America Market Incremental $ Opportunity, 2025 to 2035
- Figure 18: Western Europe Market Incremental $ Opportunity, 2025 to 2035
- Figure 19: Eastern Europe Market Incremental $ Opportunity, 2025 to 2035
- Figure 20: East Asia Market Incremental $ Opportunity, 2025 to 2035
- Figure 21: South Asia & Pacific Market Incremental $ Opportunity, 2025 to 2035
- Figure 22: Middle East & Africa Market Incremental $ Opportunity, 2025 to 2035
- Figure 23: North America Market Value Share and BPS Analysis by Country, 2025 and 2035
- Figure 24: North America Market Value Share and BPS Analysis by Disease Type, 2025 and 2035
- Figure 25: North America Market Y-o-Y Growth Comparison by Disease Type, 2025 to 2035
- Figure 26: North America Market Attractiveness Analysis by Disease Type
- Figure 27: North America Market Value Share and BPS Analysis by Technology, 2025 and 2035
- Figure 28: North America Market Y-o-Y Growth Comparison by Technology, 2025 to 2035
- Figure 29: North America Market Attractiveness Analysis by Technology
- Figure 30: North America Market Value Share and BPS Analysis by End User, 2025 and 2035
- Figure 31: North America Market Y-o-Y Growth Comparison by End User, 2025 to 2035
- Figure 32: North America Market Attractiveness Analysis by End User
- Figure 33: Latin America Market Value Share and BPS Analysis by Country, 2025 and 2035
- Figure 34: Latin America Market Value Share and BPS Analysis by Disease Type, 2025 and 2035
- Figure 35: Latin America Market Y-o-Y Growth Comparison by Disease Type, 2025 to 2035
- Figure 36: Latin America Market Attractiveness Analysis by Disease Type
- Figure 37: Latin America Market Value Share and BPS Analysis by Technology, 2025 and 2035
- Figure 38: Latin America Market Y-o-Y Growth Comparison by Technology, 2025 to 2035
- Figure 39: Latin America Market Attractiveness Analysis by Technology
- Figure 40: Latin America Market Value Share and BPS Analysis by End User, 2025 and 2035
- Figure 41: Latin America Market Y-o-Y Growth Comparison by End User, 2025 to 2035
- Figure 42: Latin America Market Attractiveness Analysis by End User
- Figure 43: Western Europe Market Value Share and BPS Analysis by Country, 2025 and 2035
- Figure 44: Western Europe Market Value Share and BPS Analysis by Disease Type, 2025 and 2035
- Figure 45: Western Europe Market Y-o-Y Growth Comparison by Disease Type, 2025 to 2035
- Figure 46: Western Europe Market Attractiveness Analysis by Disease Type
- Figure 47: Western Europe Market Value Share and BPS Analysis by Technology, 2025 and 2035
- Figure 48: Western Europe Market Y-o-Y Growth Comparison by Technology, 2025 to 2035
- Figure 49: Western Europe Market Attractiveness Analysis by Technology
- Figure 50: Western Europe Market Value Share and BPS Analysis by End User, 2025 and 2035
- Figure 51: Western Europe Market Y-o-Y Growth Comparison by End User, 2025 to 2035
- Figure 52: Western Europe Market Attractiveness Analysis by End User
- Figure 53: Eastern Europe Market Value Share and BPS Analysis by Country, 2025 and 2035
- Figure 54: Eastern Europe Market Value Share and BPS Analysis by Disease Type, 2025 and 2035
- Figure 55: Eastern Europe Market Y-o-Y Growth Comparison by Disease Type, 2025 to 2035
- Figure 56: Eastern Europe Market Attractiveness Analysis by Disease Type
- Figure 57: Eastern Europe Market Value Share and BPS Analysis by Technology, 2025 and 2035
- Figure 58: Eastern Europe Market Y-o-Y Growth Comparison by Technology, 2025 to 2035
- Figure 59: Eastern Europe Market Attractiveness Analysis by Technology
- Figure 60: Eastern Europe Market Value Share and BPS Analysis by End User, 2025 and 2035
- Figure 61: Eastern Europe Market Y-o-Y Growth Comparison by End User, 2025 to 2035
- Figure 62: Eastern Europe Market Attractiveness Analysis by End User
- Figure 63: East Asia Market Value Share and BPS Analysis by Country, 2025 and 2035
- Figure 64: East Asia Market Value Share and BPS Analysis by Disease Type, 2025 and 2035
- Figure 65: East Asia Market Y-o-Y Growth Comparison by Disease Type, 2025 to 2035
- Figure 66: East Asia Market Attractiveness Analysis by Disease Type
- Figure 67: East Asia Market Value Share and BPS Analysis by Technology, 2025 and 2035
- Figure 68: East Asia Market Y-o-Y Growth Comparison by Technology, 2025 to 2035
- Figure 69: East Asia Market Attractiveness Analysis by Technology
- Figure 70: East Asia Market Value Share and BPS Analysis by End User, 2025 and 2035
- Figure 71: East Asia Market Y-o-Y Growth Comparison by End User, 2025 to 2035
- Figure 72: East Asia Market Attractiveness Analysis by End User
- Figure 73: South Asia & Pacific Market Value Share and BPS Analysis by Country, 2025 and 2035
- Figure 74: South Asia & Pacific Market Value Share and BPS Analysis by Disease Type, 2025 and 2035
- Figure 75: South Asia & Pacific Market Y-o-Y Growth Comparison by Disease Type, 2025 to 2035
- Figure 76: South Asia & Pacific Market Attractiveness Analysis by Disease Type
- Figure 77: South Asia & Pacific Market Value Share and BPS Analysis by Technology, 2025 and 2035
- Figure 78: South Asia & Pacific Market Y-o-Y Growth Comparison by Technology, 2025 to 2035
- Figure 79: South Asia & Pacific Market Attractiveness Analysis by Technology
- Figure 80: South Asia & Pacific Market Value Share and BPS Analysis by End User, 2025 and 2035
- Figure 81: South Asia & Pacific Market Y-o-Y Growth Comparison by End User, 2025 to 2035
- Figure 82: South Asia & Pacific Market Attractiveness Analysis by End User
- Figure 83: Middle East & Africa Market Value Share and BPS Analysis by Country, 2025 and 2035
- Figure 84: Middle East & Africa Market Value Share and BPS Analysis by Disease Type, 2025 and 2035
- Figure 85: Middle East & Africa Market Y-o-Y Growth Comparison by Disease Type, 2025 to 2035
- Figure 86: Middle East & Africa Market Attractiveness Analysis by Disease Type
- Figure 87: Middle East & Africa Market Value Share and BPS Analysis by Technology, 2025 and 2035
- Figure 88: Middle East & Africa Market Y-o-Y Growth Comparison by Technology, 2025 to 2035
- Figure 89: Middle East & Africa Market Attractiveness Analysis by Technology
- Figure 90: Middle East & Africa Market Value Share and BPS Analysis by End User, 2025 and 2035
- Figure 91: Middle East & Africa Market Y-o-Y Growth Comparison by End User, 2025 to 2035
- Figure 92: Middle East & Africa Market Attractiveness Analysis by End User
- Figure 93: Global Market - Tier Structure Analysis
- Figure 94: Global Market - Company Share Analysis
- FAQs -
How big is the RNA Editing for Neurodegenerative Diseases Market in 2025?
The global RNA Editing for Neurodegenerative Diseases Market is valued at USD 125.0 million in 2025.
What will be the size of the RNA Editing for Neurodegenerative Diseases Market in 2035?
The size of the RNA Editing for Neurodegenerative Diseases Market is projected to reach USD 847.9 million by 2035.
How much will the RNA Editing for Neurodegenerative Diseases Market grow between 2025 and 2035?
The RNA Editing for Neurodegenerative Diseases Market is expected to grow at a 21.1?GR between 2025 and 2035.
Who are the prominent players in the RNA Editing for Neurodegenerative Diseases Market?
Prominent players in the market include Shape Therapeutics, Korro Bio, ProQR Therapeutics, Wave Life Sciences, Roche, Biogen, Novartis, Bristol Myers Squibb, Alnylam Pharmaceuticals, and Ionis Pharmaceuticals.
RNA Editing for Neurodegenerative Diseases Market